GERON CORP (GERN)
About GERON CORP
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2023
- $237.0K
- Net income
- -$83.5M
- Total assets
- $570.5M
- Market cap
- $750.6M
- Operating margin
- -37.3%
- Net margin
- -45.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $183.9M
- Operating expenses
- $252.5M
- Operating income
- -$68.6M
- Income tax
- $75.0K
- Net income
- -$83.5M
- EPS (basic)
- $-0.13
- EPS (diluted)
- $-0.13
Balance sheet
- Total assets
- $570.5M
- Current assets
- $520.3M
- Total liabilities
- $344.7M
- Current liabilities
- $111.5M
- Shareholders’ equity
- $225.9M
Cash flow
- Operating cash flow
- -$111.0M
- Investing cash flow
- $107.2M
- Financing cash flow
- $2.3M
- Net cash flow
- -$1.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $750.6M
- EPS (diluted)
- $-0.13
- Shares outstanding
- 528.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 31, 1996
Geron Corp (GERN) Stock Price
- Reported a net loss of $83.5M in FY2023.
- Revenue grew 13100% from FY2021 to FY2025.
- Trading 27% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review GERON CORP.
Write a review
News about GERON CORP
News & sentiment via Polygon.io
Geron Corp: frequently asked questions
Is Geron Corp an American company?
Geron Corp is a US-based company headquartered in Foster City, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Geron Corp headquartered?
Geron Corp is headquartered in Foster City, California, United States.
Is Geron Corp publicly traded?
Yes — Geron Corp is a publicly traded company. Its stock trades under the ticker symbol GERN on the NASDAQ.
What does Geron Corp do?
Geron Corp is an American Pharmaceuticals company in the Health & Beauty sector.
When was Geron Corp founded?
Geron Corp was founded in 1990.
